Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART123 in Relapsed/Refractory CD123+ Hematologic Malignancies
NCT06765876Phase 1Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Transfusion
- Start
- Oct 2024
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART123 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 1 more, sponsored by Institute of Hematology and Blood Transfusion. Primary endpoints: Safety and tolerability of autologous CART123 cells at 24 months, Rate of hematological recovery at 24 months and 1 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
CART123
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT06765876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765876.